Answers are grounded in this paper and cite their sources.
This randomized trial identifies inhibitors of DhhP, affecting growth and morphology in Borrelia burgdorferi, suggesting new therapeutic targets.
Second messenger signaling through cyclic dinucleotides regulates critical processes in pathogenic bacteria. DhhP is a phosphodiesterase that regulates levels of cyclic di-AMP (c-di-AMP), an essential second messenger, in Borrelia. Genetic inhibition of DhhP is lethal to Borrelia both in vitro and within a mammalian host. Here, we present the crystal structure of DhhP, revealing a heterobimetallic active site containing precisely positioned manganese and iron ions. We demonstrate specific binding sites for each metal, challenging the prevailing paradigm of homobimetallic active centers in bacterial c-di-AMP phosphodiesterases. The enzyme forms asymmetric dimers with coordinated open and closed conformations, suggesting an alternating mechanism for substrate processing. Additionally, we identified and characterized a series of small-molecule inhibitors of DhhP and demonstrated their ability to inhibit the growth of B. burgdorferi and disrupt spirochete morphology. These compounds establish proof of concept for specific targeting of bacterial c-di-AMP phosphodiesterases and further research of c-di-AMP roles in bacterial cells.
No takes yet. Share an insight, caveat, or question.
Klíma et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: